Stephen V. Frye, PhD
Stephen Frye is Professor and Director of the Center for Integrative Chemical Biology and Drug Discovery at UNC-Chapel Hill. His research focuses on oncology drug discovery and the chemical biology of chromatin regulation. Before joining UNC in 2007, he served as worldwide Vice President for High Throughput and Discovery Medicinal Chemistry at GlaxoSmithKline. During his 20 years at GSK, his creation and leadership of a department focused on oncology and protein kinases resulted in the discovery of several marketed drugs and he is also the inventor of Avodart, GlaxoSmithKline’s drug approved for treatment of benign prostate disease.
The Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy
The Center for Integrative Chemical Biology and Drug Discovery was created with the mission of bringing dedicated medicinal chemistry expertise to bear on biological targets of therapeutic relevance under investigation by UNC faculty. Synthetic chemists, assay development and compound profiling scientists work in the Center and create dedicated, multidisciplinary project teams with other groups on campus in order to progress targets through the drug discovery and development process.”